Highlights of HIV research

Biological Valley BIOON, October 30, 2018: Human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS), is a virus that causes human immune deficiency. In 1983, HIV was first discovered in the United States. It is a kind of slow virus (lentivirus) that infects human immune system cells, and is a kind of retrovirus. By destroying human T lymphocytes, HIV interrupts cellular and humoral immune processes, leading to the paralysis of the immune system, resulting in the spread of various diseases in the human body, eventually leading to AIDS. Because of the rapid variation of HIV, it is difficult to produce specific vaccines. So far, there is no effective treatment method, which poses a great threat to human health.gay massage
Since the 80s of last century, the epidemic of AIDS has claimed more than 34 million lives. According to the World Health Organization (WHO), it is estimated that 36.9 million people worldwide will be infected with HIV in 2017, and only 59% of those infected with HIV will receive antiretroviral therapy (ART). HIV remains one of the world's greatest public health challenges so far, and there is an urgent need to delve into the function of HIV to help researchers develop new therapies that can effectively combat the disease. In order to prevent the virus from replicating in large quantities and causing damage to the immune system, people infected with HIV need to take ART daily or even for life. Although ART has been shown to be effective in suppressing the onset of AIDS, these drugs are expensive, time-consuming and have serious side effects. People urgently need to find ways to cure HIV infection.male massage
What are the major HIV studies or findings in the past October? Bio-Valley Editor combs the news about HIV research reported by Bio-Valley this month for you to read.
1. Nature: significant progress! Combination of TLR7 agonist and extensive neutralizing antibody can kill latent HIV virus bank.
In a new study, Barouch and his colleagues confirmed that a combination of broad neutralizing antibodies (bNAb) targeting HIV and Toll-like receptor 7 (TLR7) agonists that stimulate the innate immune system could delay the HIV rebound in monkeys that stopped taking ART drugs. These findings suggest that this two-pronged approach represents a potential strategy for targeting the virus library. The results were published online in the Journal Nature on 3 October 2008 under the title "Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys".
Barouch and his colleagues studied 44 rhesus monkeys infected with HIV-like virus (SHIV) and began ART therapy for two and a half years a week after infection. After 96 weeks, the Ganges RIver monkeys were divided into four groups. One group, the control group, did not receive any further research treatment. The other two groups were given TLR7 agonists or only bNAb antibodies. The fourth groups were given TLR7 agonist and bNAb antibody simultaneously. All rhesus monkeys continued to receive ART medication until the treatment was stopped at 130 weeks, when the researchers began monitoring the monkeys for signs of a rebound in SHIV in their blood.
As expected, all rhesus monkeys in the control group experienced a rapid SHIV rebound and had relatively high viral load peaks, as did almost all rhesus monkeys given the TLR7 agonist alone. But five of the 11 rhesus monkeys treated with this combination did not experience a rebound in SHIV within six months. In addition, six other rhesus monkeys with a rebound in SHIV showed lower peak viral load than the control group. Rhesus monkeys given only bNAb antibodies showed a detectable rebound in HIV, but the rebound was delayed.gay spa
2. Science sub issue: cure HIV infection! Anti alpha 4 beta 7 therapy weakens lymphocyte aggregation in gastrointestinal tract of HIV infected patients
In a new study, researchers from the Icahn Medical College in Mount Sinai and other research institutes describe for the first time a mechanism that may lead to a reduction in the number of immune cells in the gastrointestinal tract called lymphoid aggregates, where lymphocyte aggregation is an important refuge to maintain the HIV virus pool. Given the important role of the gut in HIV infection, these findings may be of interest to scientists involved in the study of cures for HIV infection. The results were published in the October 3, 2008 issue of the Journal Science Translational Medicine, entitled "Anti-alpha 4-beta 7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals". The writer is Saurabh Mehandru, associate professor of Medicine (Gastroenterology) of Icahn Medical College, Mount Sinai.gay sauna
The researchers designed an experiment involving six people with mild inflammatory bowel disease (IBD) and HIV-1 infection receiving anti-alpha-4 beta-7 drugs, especially vedolizumab (VDZ). VDZ has become the first-line drug to control the condition of IBD patients, in these patients, it shows strong efficacy and excellent safety. They studied immune cells in the blood and intestines and described the immunological and virological effects of VDZ treatment within 30 weeks.
3. Nat Commun: new long-acting injections are expected to prevent and treat HIV infection.
A persistent challenge to HIV treatment and prevention is the need to stick to medication, which allows patients to take medicines as required to achieve the best results. Now, once a day pills are available to prevent HIV infection. For some patients, however, stick to a daily medication strategy.boy massage